41Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Colombia
Neuroscience Intelligence
Colombia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #44 of 50 · Data maturity A · Research score 28.3 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:35 UTC.
11Recruiting trials
15Publications
21Institutions
Executive interpretation
Colombia ranks #44 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC106 recruiting
Washington University School of Medicine33 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
Forest Laboratories20 recruiting
Hoffmann-La Roche20 recruiting
AbbVie20 recruiting
Pfizer20 recruiting
Sumitomo Pharma America, Inc.20 recruiting
Fundación Cardiovascular de Colombia11 recruiting
AstraZeneca10 recruiting
Disease activity
Parkinsons10trials
Schizophrenia3trials
Stroke3trials
Alzheimers3trials
Depression3trials
Pain Neuropathy3trials
Other Neurology3trials
Epilepsy2trials
Autism2trials
Traumatic Brain Injury1trials
Research institutions
Universidad de AntioquiaOpenAlexlinked institution
International Center for Tropical AgricultureOpenAlexlinked institution
Instituto Nacional de SaludOpenAlexlinked institution
University of CaldasOpenAlexlinked institution
Universidad De SantanderOpenAlexlinked institution
Universidad Nacional de ColombiaOpenAlexlinked institution
Institución Universitaria Visión de las AméricasOpenAlexlinked institution
Hospital Universitario San IgnacioOpenAlexlinked institution
Meditech FoundationOpenAlexlinked institution
University of the CoastOpenAlexlinked institution
Clinical evidence trail
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06895005Transcutaneous Auricular Vagus Nerve Stimulation in Patients With StrokeNOT_YET_RECRUITING
NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRECRUITING
NCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)ACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)ACTIVE_NOT_RECRUITING
NCT06986343Impact of Palatal Expansion and Up-Locker Activator on Sleep and Pharyngeal Dimensions in ChildrenENROLLING_BY_INVITATION
Research evidence trail
PUBMEDA longitudinal examination of gut microbiota dysbiosis and neuro-behavioral phenotypes of poly(I:C)-maternal immune activation in a preclinical model of autism and schizophrenia.2026-11-01
PUBMEDContrasting clinical trajectories in two ALS patients with rare FUS variants: implications for variant interpretation, penetrance, and trial readiness.2026-10-08
PUBMEDChanges in EEG-derived entropy are associated with symptom improvement in major depressive disorder following electroconvulsive therapy.2026-10-01
PUBMEDUnlocking global neurosurgery: how telemedicine addresses unmet needs and future prospects - a scoping review.2026-10-01
PUBMEDComparison of recommendations for initial adult traumatic brain injury management across clinical practice guidelines and consensus statements: a scoping review.2026-10-01
PUBMEDReduced FOXP3 expression and its association with genetic ancestry in neuromyelitis Optica spectrum disorder: a Colombian cohort.2026-10-01
PUBMEDNeuromonitoring in the Decompressed Brain: Rethinking Physiology, Monitoring, and Thresholds After Decompressive Craniectomy.2026-09-24
PUBMEDNoninvasive Neuromonitoring in Pediatric Traumatic Brain Injury: A Scoping Review of Quantitative Pupillometry and the Evidence Gap in Noninvasive Intracranial Pressure Waveform Analysis.2026-09-01
PUBMEDFXTAS and the Spectrum of FMR1 Premutation-Associated Phenotypes in Latin America: A Scoping Review.2026-09-01
PUBMEDBrain clearance physiology in traumatic brain injury: From disruption to therapeutic potential.2026-09-01
PUBMEDCost-Effectiveness of Decompressive Craniectomy in Severe Traumatic Brain Injury Patients: A Systematic Review of Economic Studies.2026-09-01
PUBMEDPediatric Movement Disorders at a Tertiary Referral Center in Bogotá: Clinical and Epidemiological Experience From Colombia.2026-04-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.